Phaseline

Companies › Sellas Life Sciences Group

Sellas Life Sciences Group: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Galinpepimut-S
Wilms tumor protein vaccine antigen
WT1Phase 3Acute Myeloid LeukemiaDec 2026
SLS009
CDK9 inhibitor
CDK9Phase 1Hematologic MalignanciesDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04229979Galinpepimut-SPhase 3Acute Myeloid LeukemiaOncologyDec 2026
NCT04588922SLS009Phase 1Hematologic MalignanciesOncologyDec 2026

From the company's SEC filings

Cash of $138m on 2026-06-30; operating cash outflow about $33m a year; runway about 50 months at that burn, to Aug 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

CDK9 (1) WT1 (1)

Companies with the same targets

Inovio Pharmaceuticals

Companies built like this

Erasca Hutchmed Nuvation Bio GC Cell Corvus Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.